BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
See today's BioWorld
Home
» Sosei buys into Mina's small activating RNAs in potential $536M deal
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Sosei buys into Mina's small activating RNAs in potential $536M deal
May 4, 2017
By
Cormac Sheridan
No Comments
DUBLIN – Sosei Group is paying £35 million (US$45.2 million) for a 25.6 percent stake in Mina Therapeutics Ltd. in a deal that gives it a commanding view of the emerging field of small activating RNA (saRNA) therapeutics.
BioWorld